Amphastar Pharmaceuticals, Inc. is a leading US-based biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products. With a focus on ESG practices, the company also offers insulin API products. Their products are widely used in hospital and urgent care settings, distributed through various channels. Amphastar Pharmaceuticals operates in the US, China, and France, with the majority of revenue coming from the US market. With a high ESG risk rating score of 33.4, the company is committed to sustainability and governance practices in the pharmaceutical industry.